Maia Biotechnology, Inc. (MAIA) Stock Price & Analysis

Maia Biotechnology, Inc. (MAIA) rose 2.36% to USD 1.3 as of June 10, 2026 at 08:07 UTC, according to Nexqual real-time market data.

MAIA last closed at USD 1.27; the session ranged USD 1.26–1.33 on volume of 596,176 shares. Market capitalization is $79.04M, with a 52-week range of USD 0.87–3.19 (ASE). Source: Nexqual, June 10, 2026 at 08:07 UTC.

Key Statistics (as of June 10, 2026 at 08:07 UTC)

Technical Analysis (MAIA)

Nexqual's technical model rates MAIA "SELL" based on 2 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 08:07 UTC.

Analyst Ratings (MAIA)

Wall Street analysts rate MAIA "Strong Buy" based on 2 analysts, with a mean price target of USD 12.14 (range USD 10.27–14), per Nexqual as of June 10, 2026 at 08:07 UTC.

Earnings (MAIA)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 08:07 UTC.

Financials & Fundamentals (MAIA)

Source: Nexqual, June 10, 2026 at 08:07 UTC.

Financial Health Score (MAIA)

Nexqual rates Maia Biotechnology, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:07 UTC.

Ownership (MAIA)

Source: Nexqual, June 10, 2026 at 08:07 UTC.

Leadership (MAIA)

Maia Biotechnology, Inc. is led by Vlad Vitoc (age 55), Co-Founder, President, CEO & Chairman of the Board of Directors, per Nexqual as of June 10, 2026 at 08:07 UTC.

Major Backers & Investors (MAIA)

Notable institutional backers of Maia Biotechnology, Inc. include Solas Capital Management, LLC, Alyeska Investment Group, L.p., 683 Capital Management LLC, according to Nexqual as of June 10, 2026 at 08:07 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 08:07 UTC.

From Maia Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)

Key Strengths & Strategy (as disclosed to the SEC)

• All patients enrolled have previously failed 2 or more prior lines of treatment including an immune CPI and platinum-based chemotherapy for advanced NSCLC.   On October 24, 2023, we reported unprecedented interim disease control rate (DCR) of 100% in second-line treatment that far surpasses standard of care (SoC) DCR of 53-64%, presented at ESMO 2023.
• This program may also allow us to strengthen our patent portfolio.
• Our practice is to actively seek to obtain, where appropriate, intellectual property protection for our current product candidates and any future product candidates, proprietary information, and proprietary technology through a combination of patents, protection of proprietary know-how and trade secrets, and contractual arrangements, both in the United States and abroad.
• To help protect our proprietary know-how that is not patentable, we seek to put in place appropriate internal policies for the management of confidential information requiring all our employees, consultants, advisors, and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information, and which will require disclosure and assignment to us of the ideas, developments, discoveries, and inventions important to our business.

Partnerships

• All patents are method of use.       On December 23, 2020, we entered into a second agreement with UTSW, which granted the Company option rights in the UTSW1 Agreement and obtaining additional license rights.
• In February 2021, we signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant cost-savings for the study.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:07 UTC. This page is informational and not investment advice.